Baillie Gifford & CO Regeneron Pharmaceuticals, Inc. Transaction History

Baillie Gifford & CO

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	BUY	$680.49 - $826.97 $4,763 - $5,788	7 Added 14.89%	54 $44,000
Q3 2022 Oct 27, 2022	SELL	$573.97 - $724.32 $1,721 - $2,172	-3 Reduced 6.0%	47 $32,000
Q2 2022 Aug 08, 2022	BUY	$548.35 - $738.84 $2,193 - $2,955	4 Added 8.7%	50 $30,000
Q4 2021 Jan 20, 2022	SELL	$543.48 - $670.97 $4,891 - $6,038	-9 Reduced 16.36%	46 $29,000
Q3 2021 Oct 19, 2021	SELL	$574.03 - $680.96 $4,592 - $5,447	-8 Reduced 12.7%	55 $33,000
Q1 2021 May 06, 2021	BUY	$446.73 - $548.2 $1,340 - $1,644	3 Added 5.0%	63 $30,000
Q4 2020 Feb 10, 2021	BUY	$478.3 - $607.98 $28,698 - $36,478	60 New	60 $29,000
Q2 2018 Jul 17, 2018	SELL	$284.6 - $344.99 $1.57 Million - $1.9 Million	-5,500 Closed	0 $0
Q2 2017 Aug 10, 2017	BUY	N/A	5,500	5,500 $2.7 Million

1,534

83.6M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $75.2B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

Stay updated on Baillie Gifford & CO with notifications on news.